Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2014; 20(30): 10355-10367
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10355
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10355
First-line therapeutic options: |
10-d Bismuth-Furazolidone Quadruple therapy: |
Pantoprazole 40 mg BD + Amoxicillin 1 g BD + Bismuth 240 mg BD for 10 d; Metronidazole 500 mg BD just over the first 5 d and Furazolidone 200 mg BD over the second 5 d |
14-d Clarithromycin-containing Hybrid therapy: |
Pantoprazole 40 mg BD + Amoxicillin 1 g BD for 14 d and Clarithromycin 500 mg BD + Tinidazole 500 mg BD just over the last 7 d |
14-d Omeprazole-Bismuth-Tetracycline-Metronidazole, if: |
Omeprazole 20 mg BD + Bismuth 240 mg BD + Tetracycline 500 mg QID + Metronidazole 500 mg TDS for 14 d |
Second-line therapeutic options: |
14-d Omeprazole-Bismuth-Tetracycline-Furazolidone: |
Omeprazole 20 mg BD + Bismuth 240 mg BD + Tetracycline 500 mg BD + Furazolidone 200 mg BD (if Furazolidone is not used as first-line) |
14-d Ranitidine-Bismuth-Tetracycline-Metronidazole: |
Ranitidine-Bismuth 400 mg BD + Tetracycline 500 mg BD + Metroidazole 500 mg BD |
7-d Rabeprazole-Amoxicillin-Gatifloxacin: |
Rabeprazole 20 mg BD + Amoxicillin 1 g BD + Gatifloxacin 400 mg Daily |
14-d Omeprazole-Bismuth-Azithromycin-Ofloxacin: |
Omeprazole 20 mg BD + Bismuth 240 mg BD + Azithromycin 250 mg BD + Ofloxacin 200 mg BD |
Third-line therapeutic options: |
The optimal regimen must be chosen according to the pattern of antibiotic susceptibility of H. pylori1 |
-
Citation: Fakheri H, Bari Z, Aarabi M, Malekzadeh R.
Helicobacter pylori eradication in West Asia: A review. World J Gastroenterol 2014; 20(30): 10355-10367 - URL: https://www.wjgnet.com/1007-9327/full/v20/i30/10355.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i30.10355